KUALA LUMPUR, Jan 29 -- Nippon Express Bangladesh Ltd (NE Bangladesh), a local subsidiary of Tokyo-based Nippon Express Co Ltd, has obtained Good Distribution Practice (GDP) certification, effective recently, evidencing its compliance with standards for the proper distribution of pharmaceuticals applicable to air cargo import/export services.
Bangladesh has a population of approximately 170 million and annual gross domestic product growth rate of seven per cent to eight per cent. The country was expected to see 4.5 per cent growth in 2020 and 2021, despite the coronavirus pandemic.
Bangladesh's pharmaceutical market is forecast to grow from its present scale of US$3 billion to US$6 billion by 2025, with this increase to be especially conspicuous in the already booming production of generic pharmaceuticals. (US$1 = RM4.050)
Having acquired GDP certification, NE Bangladesh will be better able to respond to expanding imports of active pharmaceutical ingredients from Europe and Japan, and exports of pharmaceuticals to destinations in Europe, the Middle East, Africa and elsewhere.
According to a statement, the company will collaborate with other Nippon Express Group companies that have already obtained GDP certification to extend its services globally.
Nippon Express will continue stepping up its efforts on behalf of the pharmaceutical industry and enhancing its services to meet increasingly sophisticated and diversified pharmaceutical needs.
More details at http://www.nipponexpress.com/
-- BERNAMA
No comments:
Post a Comment